Micronoma, Inc is a pioneering company based in San Diego, CA that is revolutionizing early-stage cancer detection through their innovative Oncobiota platform. By utilizing microbiome markers in blood samples, Micronoma's platform, which combines microbial research, next-gen sequencing, and AI, offers high sensitivity and specificity in detecting cancer in its earliest stages. With a focus on one cancer at a time, starting with lung cancer, Micronoma aims to provide advanced diagnostic services to physicians, leading to actionable results, cost savings, and ultimately, more lives saved.
With their breakthrough device designation from the FDA for their OncobiotaLUNG liquid biopsy assay, Micronoma is at the forefront of diagnostic advancements. Their patent-pending technology, which analyzes cancer-related microbiome with precision, has the potential to be applied to various cancer types. By harnessing the power of the microbiome, Micronoma is dedicated to redefining early-stage detection and improving the standard of care in cancer diagnosis.
Generated from the website